⚕ GalenOps field
←

SITE014-0431

completed

A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE014 (NLD) · Dr. Moreau
consented 2023-08-17

AEs
6
Serious
0
Dropout signal
–

Adverse events

severe assessed

Grade 3 Dyspnoea — outcome: RECOVERED/RESOLVED; onset 2023-09-14 (study day 15); relationship: not assessed

mild assessed

Grade 1 Anaemia — outcome: RECOVERED/RESOLVED; onset 2023-09-20 (study day 21); relationship: not assessed

moderate assessed

Grade 2 Vomiting — outcome: RECOVERED/RESOLVED; onset 2023-10-05 (study day 36); relationship: N

moderate assessed

Grade 2 Diarrhoea — outcome: RECOVERED/RESOLVED; onset 2023-11-15 (study day 77); relationship: Y

mild assessed

Grade 1 Asthenia — outcome: RECOVERED/RESOLVED; onset 2023-12-01 (study day 93); relationship: N

mild assessed

Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-12-09 (study day 101); relationship: not assessed

Data queries

No data queries.